ATHA - Athira Pharma, Inc.

0.2843
-0.020   -6.929%

Share volume: 173,982
Last Updated: 04-25-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$0.30
-0.02
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
32%
Profitability 35%
Dept financing 6%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.22%
1 Month
-6.79%
3 Months
-45.23%
6 Months
-41.69%
1 Year
-85.57%
2 Year
-89.81%
Key data
Stock price
$0.28
P/E Ratio 
0.00
DAY RANGE
$0.28 - $0.31
EPS 
-$2.52
52 WEEK RANGE
$0.22 - $3.67
52 WEEK CHANGE
-$85.57
MARKET CAP 
22.687 M
YIELD 
N/A
SHARES OUTSTANDING 
38.439 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
2.96
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$294,171
AVERAGE 30 VOLUME 
$229,829
Company detail
CEO: Mark J. Litton
Region: US
Website: athira.com
Employees: 40
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in Phase 3 and ACT-AD clinical trials for the treatment of Alzheimer's disease.

Recent news
loading